Acadia Pharmaceuticals (ACAD) announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Officer. In this role, Tina will lead Acadia’s business development and corporate strategy and serve as a member of the Company’s Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia. Ms. Katcheves brings over two decades of experience in the biopharmaceutical industry spanning corporate strategy, M&A, and innovation leadership. Most recently, she served as Senior Vice President, Global Business Development at Teva Pharmaceuticals (TEVA), where she oversaw the expansion of Teva’s innovative medicines pipeline and built new internal and external capabilities to support long-term portfolio advancement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $36 from $32 at UBS
- ACADIA Pharmaceuticals: Strong Growth and Undervalued Pipeline Support Buy Rating
- ACADIA Pharmaceuticals Reports Strong Q2 2025 Earnings
- Acadia Pharmaceuticals price target raised to $24 from $23 at Mizuho
- Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion